Study to investigate the bioequivalence and bioavailability of different formulations containing 0.030 mg Ethinylestradiol and 0.125 mg Levonorgestrel in postmenopausal women
Please see attached Study Results Summary below.
No Inclusion Criteria Available
No Exclusion Criteria Available
Open-label, randomized, crossover study to investigate the bioequivalence of two different tablet formulations containing 0.030 mg ethinylestradiol and 0.125 mg levonorgestrel (with gelatin [SH D00133A] versus gelatinfree [SH D00342A]) and to compare the bioavailability of the gelatincontaining formulation to that of a microcrystalline suspension [SH M00133A] in healthy postmenopausal women